A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

This is an early-stage trial testing a new drug called NRM-823 in people with various advanced or metastatic cancers, including lung, breast, head and neck, esophageal, stomach, cervical, endometrial, and ovarian cancers. The goal is to find a safe dose and look for early signs of effectiveness. **You may be eligible if...** - You have been diagnosed with advanced or metastatic non-small cell lung cancer, triple-negative breast cancer, head and neck cancer, esophageal cancer, gastric cancer, or gynecologic cancers (cervical, endometrial, ovarian) - You are in good general health (ECOG 0-1) - Your liver, kidneys, heart, and blood counts are within acceptable limits **You may NOT be eligible if...** - You have received chemotherapy, biological therapy, immunotherapy, or radiation within 3 weeks before starting the study drug - You have had serious lung inflammation (pneumonitis) requiring steroids from prior treatments - You have had a prior stem cell or organ transplant - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.